Inovio stock surges after experimental Covid-19 vaccine shows long-term protection in animals
Excerpt from the article:
“Inovio’s stock climbed as much as 15% in pre-market trading Thursday after the Montgomery County biopharmaceutical company announced its Covid-19 vaccine candidate was effective in protecting non-human primates from the virus 13 weeks after the last vaccination.
The stock was up more than 6% to $20.73 per share at Thursday’s close.
According to the company, its experimental DNA-based vaccine, INO-4800, showed durable antibody and T cell responses in rhesus macaques, a monkey species, for four months.”
Click the button below to read the Article:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?